Dr Rajiv M Jhaveri, MD | |
110 Irving St Nw, Washington, DC 20010-2976 | |
(301) 946-5100 | |
(301) 929-0348 |
Full Name | Dr Rajiv M Jhaveri |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 45 Years |
Location | 110 Irving St Nw, Washington, District Of Columbia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104850411 | NPI | - | NPPES |
0129 | Other | DC | CAREFIRST BCBS |
223179 | Other | DC | KAISER |
2892173 | Other | DC | AETNA HMO |
5717639 | Medicaid | VA | |
7398020 | Other | DC | AETNA NON HMO |
288226 | Other | VA | ANTHEM BCBS |
91261800 | Medicaid | FL | |
535866 | Other | DC | NCPPO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | MD33069 (District Of Columbia) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Medstar Medical Group Anesthesiology Llc | 1052678034 | 456 |
Medstar Medical Group Anesthesiology Llc | 1052678034 | 456 |
News Archive
Drugs that affect the levels of an important brain protein involved in learning and memory reverse cellular changes in the brain seen during aging, according to an animal study in the December 7 issue of The Journal of Neuroscience. The findings could one day aid in the development of new drugs that enhance cognitive function in older adults.
The first oral medication for multiple sclerosis was approved today by the Food & Drug Administration. Physicians praised the decision to approve the drug, called fingolimod, saying it would give multiple sclerosis patients new options for treatment.
Forty years ago, children born with sickle cell disease (SCD) were not expected to live past their teenage years. Today, medical advances are allowing children to live well into adulthood, raising concerns over who is going to care for these patients as adults. However, programs are underway to address these concerns, as reported in the March/April edition of Journal of Pediatric Oncology Nursing, published by the Association of Pediatric Hematology/Oncology Nurses (APHON).
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).
› Verified 3 days ago
Entity Name | Medstar Medical Group Anesthesiology Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1528578333 PECOS PAC ID: 1052678034 Enrollment ID: O20171207001966 |
News Archive
Drugs that affect the levels of an important brain protein involved in learning and memory reverse cellular changes in the brain seen during aging, according to an animal study in the December 7 issue of The Journal of Neuroscience. The findings could one day aid in the development of new drugs that enhance cognitive function in older adults.
The first oral medication for multiple sclerosis was approved today by the Food & Drug Administration. Physicians praised the decision to approve the drug, called fingolimod, saying it would give multiple sclerosis patients new options for treatment.
Forty years ago, children born with sickle cell disease (SCD) were not expected to live past their teenage years. Today, medical advances are allowing children to live well into adulthood, raising concerns over who is going to care for these patients as adults. However, programs are underway to address these concerns, as reported in the March/April edition of Journal of Pediatric Oncology Nursing, published by the Association of Pediatric Hematology/Oncology Nurses (APHON).
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Rajiv M Jhaveri, MD 11510 Georgia Ave, Suite 206, Wheaton, MD 20902-1925 Ph: (301) 946-5100 | Dr Rajiv M Jhaveri, MD 110 Irving St Nw, Washington, DC 20010-2976 Ph: (301) 946-5100 |
News Archive
Drugs that affect the levels of an important brain protein involved in learning and memory reverse cellular changes in the brain seen during aging, according to an animal study in the December 7 issue of The Journal of Neuroscience. The findings could one day aid in the development of new drugs that enhance cognitive function in older adults.
The first oral medication for multiple sclerosis was approved today by the Food & Drug Administration. Physicians praised the decision to approve the drug, called fingolimod, saying it would give multiple sclerosis patients new options for treatment.
Forty years ago, children born with sickle cell disease (SCD) were not expected to live past their teenage years. Today, medical advances are allowing children to live well into adulthood, raising concerns over who is going to care for these patients as adults. However, programs are underway to address these concerns, as reported in the March/April edition of Journal of Pediatric Oncology Nursing, published by the Association of Pediatric Hematology/Oncology Nurses (APHON).
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).
› Verified 3 days ago
Dr. Fay Horng, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7504 | |
Dr. Matthew Mueller, DO, MPH Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Dr. Shane Zamani, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 23rd St Nw, Washington, DC 20037 Phone: 202-715-4750 | |
Dr. Thomas Edward Borsari, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 50 Irving St Nw, Dept Of Anesthesiology, Washington, DC 20422 Phone: 202-745-8000 | |
Alexis Lambros, CAA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2025 | |
Susan Verghese, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2025 | |
Joan Threlfall, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 |